Cells have evolved a complex network of biochemical pathways, collectively known as the
DNA damage response (DDR), to prevent detrimental mutations from being passed on to …

Tumour heterogeneity and a long-standing paucity of effective therapies other than
chemotherapy have contributed to triple-negative breast cancer (TNBC) being the subtype …

Metastatic breast cancer (MBC) is an incurable disease, but survival improvements have
been reported with appropriate therapeutic strategies. 1-8 Systemic therapy is the standard …

Genomic instability is the hallmark of various cancers with the increasing accumulation of
DNA damage. The application of radiotherapy and chemotherapy in cancer treatment is …

Hormone receptor (HR)‐positive and human epidermal growth factor receptor 2 (HER2)‐
negative breast cancer is defined by the presence of the estrogen receptor and/or the …

Loss-of-function mutations in BRCA1 and BRCA2 are detected in at least 5% of unselected
patients with breast cancer (BC). These BC susceptibility genes encode proteins critical for …

Background Primary analyses of the phase III BrighTNess trial showed addition of
carboplatin with/without veliparib to neoadjuvant chemotherapy significantly improved …

Triple-negative breast cancer (TNBC) is not a unique disease, encompassing multiple
entities with marked histopathological, transcriptomic and genomic heterogeneity. Despite …

Talazoparib, a PARP inhibitor, is active in germline BRCA1 and BRCA2 (g BRCA1/2)-mutant
advanced breast cancer, but its activity beyond g BRCA1/2 is poorly understood. We …

Simple Summary Triple negative breast cancer (TNBC) represents 15 to 20% of all breast
cancers in the United States. The main treatment option remains chemotherapy, despite …